Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Sheppard Pratt)
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
An investigational probiotic supplement comprising two bacterial strains, *Lactobacillus rhamnosus* LGG® and *Bifidobacterium animalis subsp. lactis* BB-12®, being developed and studied by Sheppard Pratt Health System for psychiatric disorders. It is currently in a Phase 2 clinical trial for the prevention of relapse in individuals recently hospitalized for bipolar depression. [2, 3] The proposed mechanism of action involves modulating the gut-brain axis and reducing gut inflammation, which is believed to be a contributing factor in the symptoms of bipolar disorder. [4, 5] Previous research by the same team indicated that this probiotic combination was effective in reducing rehospitalization rates for patients with acute mania. [6, 8]
- Other names
- probiotic supplement-Sheppard Pratt Health System-bipolar depression
Beyond the preview
Go deeper on Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Sheppard Pratt).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Sheppard Pratt).